Abstract
Mathematical modelling is used to estimate the effectiveness of HPV vaccination. These estimates depend strongly on herd immunity and thus on naturally acquired immunity, a mechanism of which little is known. We estimated the impact of different vaccination strategies on HPV-16 and HPV-18 transmission and cervical cancer incidence in the Netherlands, considering different acquired immunity mechanisms. We used the STDSIM microsimulation model, and considered two mechanisms for acquired immunity after infection: (I) full immunity with variable duration; (II) cumulatively decreasing susceptibility to reinfection. Girls aged 13-16 years received vaccination (94.7% efficacy for HPV-16 and 92.3% for HPV-18) during a once-off catch-up campaign with 50% coverage, followed by annual vaccination of 12-year-old girls (60% coverage). Alternative vaccination scenarios included increased coverage, including boys, and lower vaccine efficacy. HPV-16 incidence reduced by 64% under mechanism I and 75% under mechanism II; HPV-18 incidence reduced by 58% and 73%, respectively, and these reductions lead to 48-56% fewer cervical cancer cases. Increasing coverage can lead to over 96% reduction in HPV incidence. Vaccinating boys reduced incidence by 7...Continue Reading
References
Apr 26, 2000·AIDS·E L KorenrompJ D Habbema
Apr 1, 2004·International Journal of Cancer. Journal International Du Cancer·Nicole W J BulkmansChris J L M Meijer
Jan 1, 2005·The Journal of Infectious Diseases·Geoffrey P Garnett
Jun 27, 2006·Archives of Sexual Behavior·Ron de GraafMargreet ten Have
Nov 18, 2008·PloS One·Charlotte H LenselinkRuud L M Bekkers
Nov 17, 2009·Vaccine·Yoon Hong ChoiWilliam John Edmunds
Jun 25, 2010·Vaccine·Nicolas Van de VeldeMarie-Claude Boily
Jul 22, 2010·BMJ : British Medical Journal·UNKNOWN FUTURE I/II Study GroupRichard Haupt
Oct 7, 2010·Sexually Transmitted Infections·Marc BrissonMarie-Claude Boily
Oct 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Inge M C M de KokMarjolein van Ballegooijen
Dec 15, 2010·Vaccine·Iacopo BaussanoPaolo Vineis
Feb 4, 2011·The New England Journal of Medicine·Anna R GiulianoDalya Guris
May 5, 2011·Epidemiology·Johannes A BogaardsJohannes Berkhof
Aug 23, 2011·International Journal of Cancer. Journal International Du Cancer·A SzarewskiUNKNOWN HPV PATRICIA Study Group
Nov 15, 2011·The Lancet Oncology·Matti LehtinenUNKNOWN HPV PATRICIA Study Group
Dec 30, 2011·PLoS Medicine·Johannes A BogaardsJacco Wallinga
Feb 11, 2012·International Journal of Cancer. Journal International Du Cancer·Peng GuanGary M Clifford
Aug 28, 2012·The Lancet Infectious Diseases·Talía MalagónMarc Brisson
Jan 9, 2013·Journal of the National Cancer Institute·Ahmedin JemalBrenda K Edwards
Feb 26, 2013·Vaccine·Igor A KorostilDavid G Regan
Mar 23, 2013·Vaccine·J HornR T Mikolajczyk
Jan 21, 2014·Infectious Agents and Cancer·Iacopo BaussanoSilvia Franceschi
Mar 13, 2014·The Journal of Infectious Diseases·Silvia Franceschi, Iacopo Baussano
Apr 1, 2014·BMC Public Health·Madelief MollersAdriana Tami
Apr 17, 2014·British Journal of Cancer·K KavanaghM Donaghy
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Paulo S NaudDominique Descamps
Feb 3, 2015·PloS One·Suzette M MatthijsseSake J de Vlas
Citations
Dec 17, 2015·Cancer·Brittany L BychkovskyPaul E Goss
Jun 23, 2016·The Journal of Infectious Diseases·Suzette M MatthijsseSake J de Vlas
Sep 5, 2018·PloS One·Suzette M MatthijsseSake J de Vlas
Nov 13, 2018·Expert Review of Vaccines·V QendriJ Berkhof
Apr 11, 2021·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Emi NaslaziInge M C M de Kok